ExpreS2ion Biotech Holding AB

EXPRS2 · Nasdaq Stockholm · Healthcare

1.09SEK −6.0%last day

Price as of 2 October 2026

The price over the past year, with dividends: −94.4%

Performance

1 month

−21.5%

1 year

−94.4%

3 years, per year

−72.6%

5 years, per year

−76.2%

Largest fall, 3 years

−99.3%

Below the peak now

−99.9%

Volatility, 1 year

192.9%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

0.9

Dividend yield

0.0%

Return on equity

−86.0%

Net margin

−152.3%

Market value

4 m USD

Quality, value and trend

Where ExpreS2ion Biotech Holding stands against every Nordic stock today. 100 is best.

Quality58

Profitability and a sound balance sheet over time. Better than 58% of Nordic stocks.

Value20

The price measured against earnings, assets and cash flow. Better than 20% of Nordic stocks.

Trend2

The price development over the past year. Better than 2% of Nordic stocks.

Combined10

Quality, value and trend together. Better than 10% of Nordic stocks.

About ExpreS2ion Biotech Holding

ExpreS2ion Biotech Holding AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 19 employees.

ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vaccines for Nipah virus, Malaria, and influenza. It also offers GlycoX-S2, a glyco-engineered variants of the ExpreS2 platform to modify glycosylation patterns in expressed proteins. The company has collaboration agreement with University of Oxford for the development of vaccine for malaria.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis